摘要
目的:探讨新辅助化疗在Ⅲ期非小细胞肺癌患者的临床价值。方法:对287例Ⅲ期非小细胞肺癌进行分析研究,其中单纯手术或手术+术后化疗242例(A组);术前化疗+手术+术后化疗45例(B组),术前化疗采用丝裂霉素+西艾克+顺铂(MVP)方案,术后化疗同A组。对两组手术切除率、并发症发生率、术后1、3、5年生存率进行统计学分析。结果:手术切除率B组明显高于A组(P<0.05),术后并发症发生率相近(P>0.05)。术后1、3年生存率两组相近(P>0.05)。5年生存率B组高于A组(P<0.05)。结论:对术前有手术切除困难但经诱导化疗后肿瘤明显缩小的Ⅲ期非小细胞肺癌的患者,宜提倡术前化疗+手术+术后化疗或/和术后化疗。
Objective: To analyze the results of these treatments in patients with stage Ⅲ non-small cell lung cancer selectly and study the value of neoadjuvant chemotherapy in patients with stage Ⅲ non-small cell lung cancer. Methods: This research performed a retrospective analysis of 287 patients with stage Ⅲ non-small cell lung cancer in our hospital enrolled in the protocol between January 1989 and May 1998. In group A, 116 cases administered operation alone and 126 cases accepted operation and postoperative chemotherapy consisting of 3-4 courses of etoposide(100 mg/m2, days1-5),adriamycin(50 mg/m2,day1), and cisplatin (90 mg/m2,day1) every 4 weeks; 45 cases(Group B) accepted neoadjuvant chemotherapy, operation and postoperative chemotherapy. The regimen of neoadjuvant chemotherapy consist of 1-3 courses mitomycin C(6 mg/m2, day1),vindesine(2.5 mg/m2, day1,8),cisplatin(20-30 mg/m2,day3-5) every 4 weeks; The regimen of postoperative chemotherapy was the same as Group A. All data were analysed with SPSS statistical software. Results: Group B had higher resectable rate than Group A(P < 0.05). The rates of morbidity and 1,3-year survival in these groups close by(P > 0.05). But the rate of 5-year survival of Group B were higher than Group A(P < 0.05). Conclusion: The patient with stage ⅢA/B who have good prognosis in neoadjuvant chemotherapy should accept neoadjuvant chemotherapy + operation + postoperative chemotherapy.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2005年第1期49-51,共3页
Journal of Nanjing Medical University(Natural Sciences)
关键词
非小细胞肺癌
新辅助化学治疗
non-small cell lung cancer
neoadjuvant chemotherapy
